Researchers at
Ireland's Waterford Institute of Technology have been
awarded nearly $1 million to test and develop transdermal medications
for conditions such as non-melanoma skin cancer.
The drugs will be of high potency, meaning a quantity of the
candidate weighing less than a grain of sugar could be efficacious.
That's why the manufacturing facilities of Ireland's Eirgen Pharma are also being deployed in the drug delivery initiative.
"Currently, many drugs are taken orally or injected directly into the
bloodstream where they travel around the body. This is very inefficient
as most of the drug taken does not reach the target organ that you wish
to treat. In addition, many of the drugs used today are highly toxic
and delivery of these drugs around the body can result in debilitating
side effects. If we can deliver these drugs directly to the target
across the skin, for example in skin cancer treatment, we can maximize
the therapeutic effect and minimize the unpleasant side effects," said
WIT's
Dr. Peter McLoughlin.
No comments:
Post a Comment